Gene Therapies for Cancer Treatment Market Set for Sustainable Growth by 2031, Key Trends, Regional Outlook, and Forecast Analysis 2025

QY Research has recently published a research report titled, "Global Gene Therapies for Cancer Treatment Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The report offers a complete compilation of first-hand and authentic information on the global Gene Therapies for Cancer Treatment market taking into consideration market dynamics, segmentation, current developments, market trends, and competitive analysis. It also includes the qualitative and quantitative assessment by the leading industry analysts. Additionally, growth factors, micro and macroeconomic indicators, and emerging market trends are being scrutinized in the report. Impact of various factors on the global Gene Therapies for Cancer Treatment market growth has also been mapped by the report.

The researchers have done a detailed assessment on the global Gene Therapies for Cancer Treatment market with the help of suitable assumptions as well as methodologies. They have offered thoughtful insights, historical data, facts, and statistics, which will prove helpful for the market participants to strategize and make effective decisions to stay ahead of the curve.

The global market for Gene Therapies for Cancer Treatment was estimated to be worth US$ 8230 million in 2024 and is forecast to a readjusted size of US$ 30409 million by 2031 with a CAGR of 18.5% during the forecast period 2025-2031.

Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.qyresearch.in/request-sample/medical-care-gene-therapies-for-cancer-treatment-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.

Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.

Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.

Market players need to be equipped with the information regarding the current and future competitive scenario in order to keep a check on their competitors' activities as well as execute their business strategies. This report will surely suffice as the analysts have critically examined the competitive scenario and have offered reliable forecasts. With this information, companies can understand the current and future market scenario and plan their tactics to gain a competitive edge over others.

Key Players Mentioned in the Global Gene Therapies for Cancer Treatment Market Research Report:

Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute

The research report provides analysis based on the global Gene Therapies for Cancer Treatment market segments including product types, end user, application, and geography. Each and every segment has been studied on the basis of factors such as market share, market size, CAGR, demand, and growth potential. Moreover, the market analysts have identified the leading regions having growth potential. This segmental study will assist the key players to stress on key growth areas of the global Gene Therapies for Cancer Treatment market and according plan their further strategies.

Segment by Type:

Viral Vectors
Non-viral Vectors

Segment by Application:

Solid Tumors
Hematologic Malignancies

Key regions including but not limited to North America, Asia Pacific, Europe, and the MEA are exhaustively analyzed based on market size, CAGR, market potential, economic and political factors, regulatory scenarios, and other significant parameters. The regional analysis provided in the Gene Therapies for Cancer Treatment report will help market participants to identify lucrative and untapped business opportunities in different regions and countries. It includes a special study on production and production rate, import and export, and consumption in each regional Gene Therapies for Cancer Treatment market considered for research. The report also offers detailed analysis of country-level Gene Therapies for Cancer Treatment markets.

Segment by Region

North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Important Questions Answered included in the Report:

(A) What is the market size and growth rate of the global and regional market by various segments?

(B) What is the market size and growth rate of the market for selective Countries?

(C) Which region or sub-segment is expected to drive the market in the forecast period?

(D) What factors are estimated to drive and restrain the market growth?

(E) What are the key technology and market trends shaping the market?

(F) what are the key opportunity in the market?

(G) Who are the leading manufacturers operating in the global Gene Therapies for Cancer Treatment market?

(H) Which key player accounted for the highest market share?

(I) What are the growth opportunities for the new entrants in the global Gene Therapies for Cancer Treatment market?

Request Pre-Order Enquiry or Customized Research On This Report: https://www.qyresearch.in/pre-order-inquiry/medical-care-gene-therapies-for-cancer-treatment-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table Of Content

1 Market Overview
1.1 Gene Therapies for Cancer Treatment Product Introduction
1.2 Global Gene Therapies for Cancer Treatment Market Size Forecast (2020-2031)
1.3 Gene Therapies for Cancer Treatment Market Trends & Drivers
1.3.1 Gene Therapies for Cancer Treatment Industry Trends
1.3.2 Gene Therapies for Cancer Treatment Market Drivers & Opportunity
1.3.3 Gene Therapies for Cancer Treatment Market Challenges
1.3.4 Gene Therapies for Cancer Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gene Therapies for Cancer Treatment Players Revenue Ranking (2024)
2.2 Global Gene Therapies for Cancer Treatment Revenue by Company (2020-2025)
2.3 Key Companies Gene Therapies for Cancer Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gene Therapies for Cancer Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Gene Therapies for Cancer Treatment
2.6 Gene Therapies for Cancer Treatment Market Competitive Analysis
2.6.1 Gene Therapies for Cancer Treatment Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Gene Therapies for Cancer Treatment Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapies for Cancer Treatment as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Viral Vectors
3.1.2 Non-viral Vectors
3.2 Global Gene Therapies for Cancer Treatment Sales Value by Type
3.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Type (2020-2031)
3.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Solid Tumors
4.1.2 Hematologic Malignancies
4.2 Global Gene Therapies for Cancer Treatment Sales Value by Application
4.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Application (2020-2031)
4.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Gene Therapies for Cancer Treatment Sales Value by Region
5.1.1 Global Gene Therapies for Cancer Treatment Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025)
5.1.3 Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031)
5.1.4 Global Gene Therapies for Cancer Treatment Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.2.2 North America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.3.2 Europe Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.4.2 Asia Pacific Gene Therapies for Cancer Treatment Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.5.2 South America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.6.2 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.3 United States
6.3.1 United States Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.3.2 United States Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.4.2 Europe Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.5.2 China Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.5.3 China Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.6.2 Japan Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.7.2 South Korea Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.8.2 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.9.2 India Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.9.3 India Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Profile
7.1.2 Biogen Main Business
7.1.3 Biogen Gene Therapies for Cancer Treatment Products, Services and Solutions
7.1.4 Biogen Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.1.5 Biogen Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis Gene Therapies for Cancer Treatment Products, Services and Solutions
7.2.4 Novartis Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.2.5 Novartis Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Profile
7.3.2 Gilead Sciences Main Business
7.3.3 Gilead Sciences Gene Therapies for Cancer Treatment Products, Services and Solutions
7.3.4 Gilead Sciences Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.3.5 Gilead Sciences Recent Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Profile
7.4.2 Sarepta Therapeutics Main Business
7.4.3 Sarepta Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
7.4.4 Sarepta Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.4.5 Sarepta Therapeutics Recent Developments
7.5 Sunway Biotech
7.5.1 Sunway Biotech Profile
7.5.2 Sunway Biotech Main Business
7.5.3 Sunway Biotech Gene Therapies for Cancer Treatment Products, Services and Solutions
7.5.4 Sunway Biotech Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.5.5 Sunway Biotech Recent Developments
7.6 SIBIONO
7.6.1 SIBIONO Profile
7.6.2 SIBIONO Main Business
7.6.3 SIBIONO Gene Therapies for Cancer Treatment Products, Services and Solutions
7.6.4 SIBIONO Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.6.5 SIBIONO Recent Developments
7.7 AnGes
7.7.1 AnGes Profile
7.7.2 AnGes Main Business
7.7.3 AnGes Gene Therapies for Cancer Treatment Products, Services and Solutions
7.7.4 AnGes Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.7.5 AnGes Recent Developments
7.8 Orchard Therapeutics
7.8.1 Orchard Therapeutics Profile
7.8.2 Orchard Therapeutics Main Business
7.8.3 Orchard Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
7.8.4 Orchard Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.8.5 Orchard Therapeutics Recent Developments
7.9 Human Stem Cells Institute
7.9.1 Human Stem Cells Institute Profile
7.9.2 Human Stem Cells Institute Main Business
7.9.3 Human Stem Cells Institute Gene Therapies for Cancer Treatment Products, Services and Solutions
7.9.4 Human Stem Cells Institute Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.9.5 Human Stem Cells Institute Recent Developments
8 Industry Chain Analysis
8.1 Gene Therapies for Cancer Treatment Industrial Chain
8.2 Gene Therapies for Cancer Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gene Therapies for Cancer Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Gene Therapies for Cancer Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.